DK0771817T3 - Oleatmonoestere af østrogener til behandling af obesitet og/eller overvægt - Google Patents

Oleatmonoestere af østrogener til behandling af obesitet og/eller overvægt

Info

Publication number: DK0771817T3
Authority: DK; Denmark
Prior art keywords: obesity; treatment; group; estrone; estradiol
Prior art date: 1995-10-30

Application number

DK96500140T

Other languages

English (en)

Inventor

Maria Alemany

Original Assignee

Oleoyl Estrone Developments S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-10-30

Filing date

1996-10-28

Publication date

2003-07-28

1996-10-28 Application filed by Oleoyl Estrone Developments S filed Critical Oleoyl Estrone Developments S

2003-07-28 Application granted granted Critical

2003-07-28 Publication of DK0771817T3 publication Critical patent/DK0771817T3/da

Links

208000008589 Obesity Diseases 0.000 title abstract 3
235000020824 obesity Nutrition 0.000 title abstract 3
229940011871 estrogen Drugs 0.000 title abstract 2
239000000262 estrogen Substances 0.000 title abstract 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 title abstract 2
229940049964 oleate Drugs 0.000 title 1
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 abstract 1
PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 abstract 1
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 abstract 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 1
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 abstract 1
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 abstract 1
102000004895 Lipoproteins Human genes 0.000 abstract 1
108090001030 Lipoproteins Proteins 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
206010033307 Overweight Diseases 0.000 abstract 1
235000021314 Palmitic acid Nutrition 0.000 abstract 1
235000021319 Palmitoleic acid Nutrition 0.000 abstract 1
241000700159 Rattus Species 0.000 abstract 1
235000021355 Stearic acid Nutrition 0.000 abstract 1
IMIPDPVHGGHVNH-YWVHRCQQSA-N [(8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-yl] (z)-octadec-9-enoate Chemical compound C1C[C@]2(C)C(=O)CC[C@H]2[C@@H]2CCC3=CC(OC(=O)CCCCCCC\C=C/CCCCCCCC)=CC=C3[C@H]21 IMIPDPVHGGHVNH-YWVHRCQQSA-N 0.000 abstract 1
210000000577 adipose tissue Anatomy 0.000 abstract 1
235000020661 alpha-linolenic acid Nutrition 0.000 abstract 1
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 abstract 1
235000021342 arachidonic acid Nutrition 0.000 abstract 1
210000004556 brain Anatomy 0.000 abstract 1
235000014113 dietary fatty acids Nutrition 0.000 abstract 1
RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 abstract 1
229960000452 diethylstilbestrol Drugs 0.000 abstract 1
229960005309 estradiol Drugs 0.000 abstract 1
229930182833 estradiol Natural products 0.000 abstract 1
229960001348 estriol Drugs 0.000 abstract 1
PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 abstract 1
229960003399 estrone Drugs 0.000 abstract 1
229960002568 ethinylestradiol Drugs 0.000 abstract 1
229930195729 fatty acid Natural products 0.000 abstract 1
239000000194 fatty acid Substances 0.000 abstract 1
150000004665 fatty acids Chemical class 0.000 abstract 1
238000010253 intravenous injection Methods 0.000 abstract 1
235000020778 linoleic acid Nutrition 0.000 abstract 1
239000002502 liposome Substances 0.000 abstract 1
231100000053 low toxicity Toxicity 0.000 abstract 1
230000003278 mimic effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
235000021313 oleic acid Nutrition 0.000 abstract 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 abstract 1
239000000725 suspension Substances 0.000 abstract 1
210000001519 tissue Anatomy 0.000 abstract 1
239000013585 weight reducing agent Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
- C07C69/28—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
- C07C69/58—Esters of straight chain acids with eighteen carbon atoms in the acid moiety
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)

DK96500140T 1995-10-30 1996-10-28 Oleatmonoestere af østrogener til behandling af obesitet og/eller overvægt DK0771817T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
ES9502101		1995-10-30

Publications (1)

Publication Number	Publication Date
DK0771817T3 true DK0771817T3 (da)	2003-07-28

Family

ID=8291993

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK96500140T DK0771817T3 (da)	1995-10-30	1996-10-28	Oleatmonoestere af østrogener til behandling af obesitet og/eller overvægt

Country Status (7)

Country	Link
US (1)	US5798348A (da)
EP (1)	EP0771817B1 (da)
AT (1)	ATE235505T1 (da)
DE (1)	DE69626927T2 (da)
DK (1)	DK0771817T3 (da)
ES (1)	ES2192221T3 (da)
PT (1)	PT771817E (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2321455A (en)	1997-01-24	1998-07-29	Norsk Hydro As	Lipophilic derivatives of biologically active compounds
AU4701299A (en)	1998-06-23	2000-01-10	Stuart R. Adler	Therapeutic applications of estrogenic carboxylic acids
WO2000050067A1 (en) *	1999-02-26	2000-08-31	Saltech I Göteborg Ab	Method and composition for the regulation of hepatic and extrahepatic production of insulin-like growth factor-1
AU7736300A (en)	1999-09-30	2001-04-30	Hollis-Eden Pharmaceuticals, Inc.	Therapeutic treatment of androgen receptor driven conditions
AU2005242170B2 (en) *	2000-06-26	2008-12-18	The Procter & Gamble Company	Compositions and methods for body weight management
US7025984B1 (en) *	2000-06-26	2006-04-11	The Procter & Gamble Company	Compositions and methods for body weight management
JP2004537506A (ja)	2001-03-01	2004-12-16	ホリス − イーデンファーマスーティカルズ、インコーポレイテッド	血液細胞欠乏症を治療するためのある種のステロイドの使用
ES2173049B1 (es) *	2001-03-28	2004-01-16	Oleoyl Estrone Developments S	Monoester de acido graso y estrogeno como agente antidiabetico e hipolipemiante.
US6635015B2 (en) *	2001-04-20	2003-10-21	The Procter & Gamble Company	Body weight management system
US7125568B2 (en) *	2001-08-23	2006-10-24	Sung Michael T	Lipophilic drug compositions
US20040157816A1 (en) *	2002-08-26	2004-08-12	Girouard Michael P.	Monounsaturated fatty acids and perhydrocyclopentanophenanthrene nucleus combination molecules, and their precursors, and the use of all of these as weight-loss agents
US6821961B2 (en) *	2001-08-24	2004-11-23	Michael P. Girouard	Monounsaturated fatty acids of at least 20 carbon atoms and perhydrocyclopentanophenanthrene nucleus combination molecules and their use as weight-loss agents
ES2186576B1 (es) *	2001-10-11	2004-09-16	Universitat De Les Illes Balears	Acido 2-hidroxioleico para utilizar como medicamento.
CA2543393A1 (en) *	2002-11-20	2004-06-03	Michael P. Girouard	Combination of monounsaturated fatty acids and estrogen, and their use
US7731947B2 (en)	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
AU2004212004B2 (en)	2003-02-13	2008-01-10	Albert Einstein College Of Medicine Of Yeshiva University	Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
CA2436650A1 (en) *	2003-08-06	2005-02-06	Naturia Inc.	Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
AU2005330504B2 (en)	2004-09-29	2010-10-28	Harbor Biosciences, Inc.	Steroid analogs and characterization and treatment methods
US20060084636A1 (en) *	2004-10-18	2006-04-20	Maria Alemany	Methods of using fatty-acid esters of estrogens and serotonin reuptake inhibiting compounds for reducing the body weight of a mammal and compositions containing the same
US20060084637A1 (en) *	2004-10-18	2006-04-20	Maria Alemany	Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same
WO2006083761A2 (en)	2005-02-03	2006-08-10	Alza Corporation	Solvent/polymer solutions as suspension vehicles
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
US7528791B2 (en) *	2005-08-08	2009-05-05	Wistron Neweb Corporation	Antenna structure having a feed element formed on an opposite surface of a substrate from a ground portion and a radiating element
EP2020990B1 (en)	2006-05-30	2010-09-22	Intarcia Therapeutics, Inc	Two-piece, internal-channel osmotic delivery system flow modulator
WO2008147373A2 (en) *	2006-06-26	2008-12-04	Manhattan Pharmaceuticals, Inc.	Methods and compositions for reducing body weight using an estrogen fatty ester in an oil
PL2359808T3 (pl)	2006-08-09	2013-10-31	Intarcia Therapeutics Inc	Osmotyczne systemy dostawcze i zespoły tłokowe
ES2302449B1 (es) *	2006-10-30	2009-06-12	Oleoyl-Estrone Developments, S.L.	Monoesteres de estrogenos con acido linoleico conjugado y usos de los mismos.
EP2157967B1 (en)	2007-04-23	2013-01-16	Intarcia Therapeutics, Inc	Suspension formulations of insulinotropic peptides and uses thereof
EP2085089A1 (en) *	2008-02-01	2009-08-05	KTB-Tumorforschungs GmbH	Phospholipids Containing omega-3-Fatty Acids for the Treatment of Overweight, Obesity and Addictive Behavior
EP2240155B1 (en)	2008-02-13	2012-06-06	Intarcia Therapeutics, Inc	Devices, formulations, and methods for delivery of multiple beneficial agents
EP3323423B1 (en)	2009-09-28	2020-06-17	Intarcia Therapeutics, Inc	Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20140378424A1 (en) *	2011-12-30	2014-12-25	Rosscreening, Inc.	Estrogen receptor modulators for reducing body weight
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es)	2015-06-03	2024-05-08	I2O Therapeutics Inc	Sistemas de colocación de implantes
KR20240037175A (ko)	2016-05-16	2024-03-21	인타르시아 세라퓨틱스 인코포레이티드	글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
AU2018206539A1 (en)	2017-01-03	2019-07-18	Intarcia Therapeutics, Inc.	Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US10836788B2 (en)	2019-02-05	2020-11-17	SD Chem, Inc.	Aqueous suspension compositions, formulations, and water dispersible dry compositions comprising 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone and hydrates, derivatives, and analogs thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2265976A (en) *	1937-10-25	1941-12-09	Schering Corp	Tertiary alcohols of the estrane series and their derivatives and a process for their manufacture
GB531178A (en) *	1938-07-02	1940-12-31	Chem Ind Basel	Manufacture of new esters of the oxy-stilbene series
JPH0610127B2 (ja) *	1985-02-09	1994-02-09	ライオン株式会社	養毛料
US4617298A (en) *	1985-10-22	1986-10-14	University Of Florida	Method and compositions for weight control

1996
- 1996-10-28 DK DK96500140T patent/DK0771817T3/da active
- 1996-10-28 PT PT96500140T patent/PT771817E/pt unknown
- 1996-10-28 EP EP96500140A patent/EP0771817B1/en not_active Expired - Lifetime
- 1996-10-28 AT AT96500140T patent/ATE235505T1/de not_active IP Right Cessation
- 1996-10-28 ES ES96500140T patent/ES2192221T3/es not_active Expired - Lifetime
- 1996-10-28 DE DE69626927T patent/DE69626927T2/de not_active Expired - Lifetime
- 1996-10-30 US US08/739,165 patent/US5798348A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
ES2192221T3 (es)	2003-10-01
EP0771817B1 (en)	2003-03-26
EP0771817A3 (en)	1999-04-14
DE69626927T2 (de)	2003-11-20
EP0771817A2 (en)	1997-05-07
PT771817E (pt)	2003-06-30
DE69626927D1 (de)	2003-04-30
ATE235505T1 (de)	2003-04-15
US5798348A (en)	1998-08-25

Publication	Publication Date	Title
DE69626927D1 (de)	2003-04-30	Oleat Monoester von Estrogenen zur Behandlung von Fettleibigkeit
Zampolli et al.	2006	Contrasting effect of fish oil supplementation on the development of atherosclerosis in murine models
BR9803195A (pt)	2000-01-11	Produto alimentìcio à base de gordura,e, pasta de gordura amarela de espalhar.
ES2074734T3 (es)	1995-09-16	Utilizacion de composiciones a base de alcoholes grasos, para la preparacion de emulsiones; procedimiento de preparacion de emulsiones y emulsiones asi obtenidas.
Cheng et al.	1975	Gonadal hormone specificity in the sexual behavior of ring doves
DK1037666T3 (da)	2004-02-09	Metode til forøgelse af absorptionen og transporten af lipidopløselige forbindelser ved burg af strukturerede glycerider
NO920067L (no)	1992-07-15	Foradditiv for droevtyggere
EP1198222A1 (en)	2002-04-24	Skin care composition
IL102639A (en)	1997-03-18	Compositions for inducing cytotoxic t lymphocyte responses
EP0196268A2 (de)	1986-10-01	Estriolester
FR2698269B1 (fr)	1995-01-06	Nouveaux médicaments à base d'acides gras insaturés, utilisables notamment comme antiagrégants plaquettaires et/ou comme transporteurs privilégiés vers le cerveau.
JPH02204417A (ja)	1990-08-14	甘草疎水性フラボノイド製剤
RU2007108771A (ru)	2008-09-20	Способы лечения, требующие фитокомпонентов
DK0456764T3 (da)	1994-01-31	Omega-3-fedtsyreholdig fedtemulsion til endotracheal indgift, fremstilling og anvendelse heraf
GR920300128T1 (en)	1993-03-16	Method for preparing a lipoprotein modified by the incorporation of a lipophilic active substance
Peifer et al.	1962	The lipid depressant activities of whole fish and their component oils
IES940674A2 (en)	1995-02-08	"An edible fat blend containing fish oil"
Tritapepe et al.	1976	Lithogenic bile after conjugated estrogen
WO2004045560A3 (en)	2004-07-29	Combination of monounsaturated fatty acids and estogen, and their use
Peterson et al.	1954	Effects of dietary sterols and sterol esters on plasma and liver cholesterol in the chick
RU95108891A (ru)	1997-11-10	Фармацевтическая эмульсия, содержащая биологически активные стероиды, способ получения эмульсии, применение эмульсии
Ayyad et al.	1992	Palmitic acid enhances cholesterol gallstone incidence in Sasco hamsters fed cholesterol enriched diets
Craig et al.	1968	Nutritional properties of Canadian canbra oil
Brattsand	1974	The effect of niceritrol (pentaerythritoltetra-nicotinate) and clofibrate upon hyperlipemia and atherosclerosis induced in rabbits by cholesterol-free semisynthetic diets
ES2180065T3 (es)	2003-02-01	Formulaciones de uso topico que contienen acetato de vitamina e.